PD-1/PD-L1TCR-TMAGE-C2CancerImmunotherapyExpression of the PD-1 protein by tumor cells is relatively common and has been shown to exert proliferation-inhibitory effects across various tumor types, including T-cell malignancies, non-small cell lung cancer, and colon cancer. However, harnessing ...
PD-1 (Programmed cell death-1) 抑制剂和PD-L1 (Programmedcell death-L1) 抑制剂是一组检查点抑制剂抗癌药物,可阻断细胞表面PD-1和PDL1免疫检查点蛋白的活性。免疫检查点抑制剂正在成为几类癌症的一线治疗方法[1]。PD-1和PD-L1抑制剂...
PD-1 (Programmed cell death-1) 抑制剂和PD-L1 (Programmedcell death-L1) 抑制剂是一组检查点抑制剂抗癌药物,可阻断细胞表面PD-1和PDL1免疫检查点蛋白的活性。免疫检查点抑制剂正在成为几类癌症的一线治疗方法[1]。 PD-1和PD-L1抑制剂起作用于抑制程序性死亡配体1(PD-L1)与其受体,程序性细胞死亡蛋白1(PD...
Inhibition of IFN-I signaling using a monoclonal IFNAR antibody decreased IFN-I-induced PD-L1 expression and promoted tumor-specific T cell effector responses when combined with oncolytic virotherapy. Furthermore, IFNAR blockade improved therapeutic response to oncolytic virotherapy in a manner ...
近年来,嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法在血液肿瘤治疗中取得了突破性进展。然而,由于实体瘤异于血液肿瘤的特性,CAR-T在实体瘤治疗中并未取得很好的疗效。
(s) is essential, we profiled PD-L1 expression levels on different cell types in tumor microenvironment by flow cytometry. PD-L1 expression on DCs was higher than other cells (Fig.1a). In order to define the roles of PD-L1 on DC, we generated PD-L1-conditional knockout mice(Fig.1...
This study shows that PDL1 expression by tumour cells represents a mechanism of resistance to immune-mediated cytolysis that can be abrogated by blockade of the PD1 axis. CAS PubMed PubMed Central Google Scholar Strome, S. E. et al. B7-H1 blockade augments adoptive T-cell immunotherapy ...
Similarly, at day 10, RT + α-PD-L1 reduced the numbers of PDL1+ MDSCs in both regions with tumors (Figure 4F & G). These data suggested that RT-induced PD-L1/PD-1 expression inhibited T-cell toxicity in the tumor microenvironment and induced tumor relapse [Citation12]. Furthermore,...
非小细胞肺癌对于PDL1-T细胞的治疗是有效的。但有些高突变的肿瘤中却缺乏CD8 T细胞的浸润,降低了CAR-T的疗效,因为进不去。 研究发现,肿瘤的突变有助于CD8 T细胞的浸润,但超过一定数量的突变,会导致肿瘤内部激活Wnt-betaCatenin信号通路,从而排斥CD8 T细胞的浸润。 因此本文借助研究出的这个机制,提出PDL1-T和Wnt-...
PD-1 (Programmed cell death-1) 抑制剂和PD-L1 (Programmedcell death-L1) 抑制剂是一组检查点抑制剂抗癌药物,可阻断细胞表面PD-1和PDL1免疫检查点蛋白的活性。免疫检查点抑制剂正在成为几类癌症的一线治疗方法[1]。PD-1和PD-L1抑制剂起作用于抑制程序性死亡配体1(PD-L1)与其受体,程序性细胞死亡蛋白1(PD...